<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="20104">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02027311</url>
  </required_header>
  <id_info>
    <org_study_id>ETOMI-1</org_study_id>
    <nct_id>NCT02027311</nct_id>
  </id_info>
  <brief_title>Etomidate vs. Midazolam for Sedation During ERCP</brief_title>
  <official_title>Etomidate With Meperidine vs Midazolam With Meperidine for Sedation During Endodscopic Retrograde Cholangiopancreatogram (ERCP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cheju Halla General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cheju Halla General Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recently up-coming drug, etomidate which is a modulator of GABA(gamma-Aminobutyric acid)-A
      receptor has been known that it maintains the appropriate sedative levels and affects little
      effects on respiratory system.

      The investigators are now trying to investigate that etomidate with meperidine combination
      regimen is superior to the midazolam with meperidine more effective and less harm on
      sedation during the ERCP procedure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ERCP (Endoscopic retrograde cholangiopancreatogram) is an uncomfortable and time-consuming
      procedure compared to other endoscopic procedures. Most ERCP procedure had been performed in
      sedation using tranquilizers and pain-killers.

      Until recently, midazolam and opioid combination regimen recognized as a standard therapy is
      widely used, but the sedative effect is insufficient and intermittent paradoxical reaction
      has been questioned. Another drug, such as propofol, has been known that the sedative effect
      is superior one of the midazolam but disappointed due to narrow therapeutic range of
      respiratory distress and absence of antagonist. Meanwhile, recently up-coming drug,
      etomidate which is a modulator of GABA-A receptor has been known that it maintains the
      appropriate sedative levels and affects little effects on respiratory system.

      For these advantages, this short acting sedative drug has been widely used in the emergency
      room during minor operation and in the operation room for induction. However, research on
      the efficacy during ERCP was not yet published.

      In this regards, the purpose of the investigators study is to prove the efficacy of
      etomidate for sedation and to establish new evidence based sedation guidelines during ERCP
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ramsay Sedation score (RSS) measured in preoperative, intraoperative, and recovery phase</measure>
    <time_frame>up to 90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>RSS score measured below time periods
Preoperative phase : From administration to endoscope intubation, every 5 minutes
Intraoperative phase : From intubation to withdrawal, every 5 minutes
Recovery phase : From withdrawal to full recovery up to 90 minutes, every 15 minutes
We summaries these measures in mean and standard deviation and compared means of two groups by linear mixed effect model</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vital signs: Blood pressure, heart rate, respiration rate, oxygen saturation</measure>
    <time_frame>up to 90 minutes</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complication defined hypoxia, hypotension, bradycardia and respiratory depression. Severe complication defined status needs mechanical ventilation, intubation, inotropic agent or saline.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Choledocholithiasis</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Pancreatitis</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Midazolam</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etomidate</intervention_name>
    <description>This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.</description>
    <arm_group_label>Etomidate</arm_group_label>
    <other_name>Etomidate lipro IV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.</description>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Midazolam</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Meperidine</intervention_name>
    <description>Both groups were administered same dose of meperidinie 50mg. Then elders &gt; 80 years old were administered 25mg iv bolus.</description>
    <arm_group_label>Etomidate</arm_group_label>
    <arm_group_label>Midazolam</arm_group_label>
    <other_name>Pethidine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients who are scheduled diagnositic or therapeutic ERCP.

          -  Age : more than 20 and less than 90 years old

          -  ASA(American Society of Anesthesiologists) classificiation : I, II, III

        Exclusion Criteria:Patients following

          -  Refuse to be enrolled

          -  ASA American Society of Anesthesiologists)classification IV, V

          -  Breast feeder

          -  The mentally ill

          -  Drug abuser

          -  Hypersensitivity to sedative or opioids

          -  Alcohol intoxication or dependency

          -  Body mass index (BMI) 36kg/m2 or more

          -  Unstable vital sign

               1. tachypnea, respiration rate more than 25/min or less than 10/min

               2. Oxygen saturation : 90% or less

               3. Systolic blood pressure : less than 90 mmHg or more than 180 mmHg

               4. Diastolic blood pressure : less than 50 mmHg or more than 100 mmHg

               5. Heart rate : more than 120 beat/min or less than 50 beat/min.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BYUNG HYO CHA, Dr.</last_name>
    <role>Study Chair</role>
    <affiliation>Cheju Halla General Hospital, Doreongno 65, Jeju-si Jeju Special Self-Governing Province, Korea 690-766</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1Digestive Disease Center and Department of Internal Medicine, Cheju Halla General Hospital</name>
      <address>
        <city>Jeju-si</city>
        <state>Jeju Special Self-Governing Province</state>
        <zip>690-766</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Standards of Practice Committee of the American Society for Gastrointestinal Endoscopy; Lichtenstein DR, Jagannath S, Baron TH, Anderson MA, Banerjee S, Dominitz JA, Fanelli RD, Gan SI, Harrison ME, Ikenberry SO, Shen B, Stewart L, Khan K, Vargo JJ. Sedation and anesthesia in GI endoscopy. Gastrointest Endosc. 2008 Nov;68(5):815-26. No abstract available.</citation>
    <PMID>18984096</PMID>
  </reference>
  <reference>
    <citation>Yamazaki N, Ogawa K. [Dopamine-beta-hydroxylase (DBH)]. Kokyu To Junkan. 1976 Nov;24(11):949-55. Japanese.</citation>
    <PMID>1034320</PMID>
  </reference>
  <reference>
    <citation>Bell GD. Review article: premedication and intravenous sedation for upper gastrointestinal endoscopy. Aliment Pharmacol Ther. 1990 Apr;4(2):103-22. Review.</citation>
    <PMID>2104078</PMID>
  </reference>
  <reference>
    <citation>Galletly D, Forrest P, Purdie G. Comparison of the recovery characteristics of diazepam and midazolam. Br J Anaesth. 1988 Apr;60(5):520-4.</citation>
    <PMID>3377928</PMID>
  </reference>
  <reference>
    <citation>Yüksel O, Parlak E, Köklü S, Ertugrul I, Tunç B, Sahin B. Conscious sedation during endoscopic retrograde cholangiopancreatography: midazolam or midazolam plus meperidine? Eur J Gastroenterol Hepatol. 2007 Nov;19(11):1002-6.</citation>
    <PMID>18049171</PMID>
  </reference>
  <reference>
    <citation>Radaelli F, Meucci G, Terruzzi V, Spinzi G, Imperiali G, Strocchi E, Lenoci N, Terreni N, Mandelli G, Minoli G. Single bolus of midazolam versus bolus midazolam plus meperidine for colonoscopy: a prospective, randomized, double-blind trial. Gastrointest Endosc. 2003 Mar;57(3):329-35.</citation>
    <PMID>12612511</PMID>
  </reference>
  <reference>
    <citation>Reimann FM, Samson U, Derad I, Fuchs M, Schiefer B, Stange EF. Synergistic sedation with low-dose midazolam and propofol for colonoscopies. Endoscopy. 2000 Mar;32(3):239-44.</citation>
    <PMID>10718390</PMID>
  </reference>
  <reference>
    <citation>Sipe BW, Rex DK, Latinovich D, Overley C, Kinser K, Bratcher L, Kareken D. Propofol versus midazolam/meperidine for outpatient colonoscopy: administration by nurses supervised by endoscopists. Gastrointest Endosc. 2002 Jun;55(7):815-25. Erratum in: Gastrointest Endosc 2002 Aug;56(2):324.</citation>
    <PMID>12024134</PMID>
  </reference>
  <reference>
    <citation>Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99. Epub 2009 Feb 2.</citation>
    <PMID>19188334</PMID>
  </reference>
  <reference>
    <citation>Jung M, Hofmann C, Kiesslich R, Brackertz A. Improved sedation in diagnostic and therapeutic ERCP: propofol is an alternative to midazolam. Endoscopy. 2000 Mar;32(3):233-8.</citation>
    <PMID>10718389</PMID>
  </reference>
  <reference>
    <citation>Falk J, Zed PJ. Etomidate for procedural sedation in the emergency department. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1272-7. Epub 2004 Jun 1. Review.</citation>
    <PMID>15173551</PMID>
  </reference>
  <reference>
    <citation>Hunt GS, Spencer MT, Hays DP. Etomidate and midazolam for procedural sedation: prospective, randomized trial. Am J Emerg Med. 2005 May;23(3):299-303.</citation>
    <PMID>15915401</PMID>
  </reference>
  <reference>
    <citation>Denny MA, Manson R, Della-Giustina D. Propofol and Etomidate are Safe for Deep Sedation in the Emergency Department. West J Emerg Med. 2011 Nov;12(4):399-403. doi: 10.5811/westjem.2011.5.2099.</citation>
    <PMID>22224127</PMID>
  </reference>
  <reference>
    <citation>Miner JR, Martel ML, Meyer M, Reardon R, Biros MH. Procedural sedation of critically ill patients in the emergency department. Acad Emerg Med. 2005 Feb;12(2):124-8.</citation>
    <PMID>15692132</PMID>
  </reference>
  <reference>
    <citation>Ruth WJ, Burton JH, Bock AJ. Intravenous etomidate for procedural sedation in emergency department patients. Acad Emerg Med. 2001 Jan;8(1):13-8.</citation>
    <PMID>11136141</PMID>
  </reference>
  <reference>
    <citation>Mandt MJ, Roback MG, Bajaj L, Galinkin JL, Gao D, Wathen JE. Etomidate for short pediatric procedures in the emergency department. Pediatr Emerg Care. 2012 Sep;28(9):898-904. doi: 10.1097/PEC.0b013e318267c768.</citation>
    <PMID>22929142</PMID>
  </reference>
  <reference>
    <citation>Terui T, Inomata M. Administration of additional analgesics can decrease the incidence of paradoxical reactions in patients under benzodiazepine-induced sedation during endoscopic transpapillary procedures: prospective randomized controlled trial. Dig Endosc. 2013 Jan;25(1):53-9. doi: 10.1111/j.1443-1661.2012.01325.x. Epub 2012 Jun 11.</citation>
    <PMID>23286257</PMID>
  </reference>
  <reference>
    <citation>Honan VJ. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest Endosc. 1994 Jan-Feb;40(1):86-8. No abstract available.</citation>
    <PMID>8163147</PMID>
  </reference>
  <reference>
    <citation>Ladas SD, Aabakken L, Rey JF, Nowak A, Zakaria S, Adamonis K, Amrani N, Bergman JJ, Boix Valverde J, Boyacioglu S, Cremers I, Crowe J, Deprez P, Díte P, Eisen M, Eliakim R, Fedorov ED, Galkova Z, Gyokeres T, Heuss LT, Husic-Selimovic A, Khediri F, Kuznetsov K, Marek T, Munoz-Navas M, Napoleon B, Niemela S, Pascu O, Perisic N, Pulanic R, Ricci E, Schreiber F, Svendsen LB, Sweidan W, Sylvan A, Teague R, Tryfonos M, Urbain D, Weber J, Zavoral M; European Society of Gastrointestinal Endoscopy Survey of National Endoscopy Society Members. Use of sedation for routine diagnostic upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy Survey of National Endoscopy Society Members. Digestion. 2006;74(2):69-77. Epub 2006 Nov 27.</citation>
    <PMID>17135728</PMID>
  </reference>
  <reference>
    <citation>Cohen LB, Wecsler JS, Gaetano JN, Benson AA, Miller KM, Durkalski V, Aisenberg J. Endoscopic sedation in the United States: results from a nationwide survey. Am J Gastroenterol. 2006 May;101(5):967-74.</citation>
    <PMID>16573781</PMID>
  </reference>
  <reference>
    <citation>Riphaus A, Rabofski M, Wehrmann T. Endoscopic sedation and monitoring practice in Germany: results from the first nationwide survey. Z Gastroenterol. 2010 Mar;48(3):392-7. doi: 10.1055/s-0028-1109765. Epub 2010 Feb 5.</citation>
    <PMID>20140841</PMID>
  </reference>
  <reference>
    <citation>Fanti L, Agostoni M, Casati A, Guslandi M, Giollo P, Torri G, Testoni PA. Target-controlled propofol infusion during monitored anesthesia in patients undergoing ERCP. Gastrointest Endosc. 2004 Sep;60(3):361-6.</citation>
    <PMID>15332024</PMID>
  </reference>
  <reference>
    <citation>Chen WX, Lin HJ, Zhang WF, Gu Q, Zhong XQ, Yu CH, Li YM, Gu ZY. Sedation and safety of propofol for therapeutic endoscopic retrograde cholangiopancreatography. Hepatobiliary Pancreat Dis Int. 2005 Aug;4(3):437-40.</citation>
    <PMID>16109532</PMID>
  </reference>
  <reference>
    <citation>Kongkam P, Rerknimitr R, Punyathavorn S, Sitthi-Amorn C, Ponauthai Y, Prempracha N, Kullavanijaya P. Propofol infusion versus intermittent meperidine and midazolam injection for conscious sedation in ERCP. J Gastrointestin Liver Dis. 2008 Sep;17(3):291-7.</citation>
    <PMID>18836622</PMID>
  </reference>
  <reference>
    <citation>Carrasco G. Instruments for monitoring intensive care unit sedation. Crit Care. 2000;4(4):217-25. Epub 2000 Jul 13. Review.</citation>
    <PMID>11094504</PMID>
  </reference>
  <reference>
    <citation>Frade Mera MJ, Guirao Moya A, Esteban Sánchez ME, Rivera Alvarez J, Cruz Ramos AM, Bretones Chorro B, Viñas Sánchez S, Jacue Izquierdo S, Montane López M. [Analysis of 4 sedation rating scales in the critical patient]. Enferm Intensiva. 2009 Jul-Sep;20(3):88-94. Spanish.</citation>
    <PMID>19775565</PMID>
  </reference>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 3, 2014</lastchanged_date>
  <firstreceived_date>April 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cheju Halla General Hospital</investigator_affiliation>
    <investigator_full_name>Byung Hyo Cha, MD</investigator_full_name>
    <investigator_title>Director of Endoscopy clinic, Digestive Disease Center, Department of Internal Medicine</investigator_title>
  </responsible_party>
  <keyword>Endoscopic Retrograde Cholangiopancreatography (ERCP)</keyword>
  <keyword>Conscious Sedation</keyword>
  <keyword>etomidate</keyword>
  <keyword>midazolam</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Pancreatitis</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Choledocholithiasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Meperidine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Etomidate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
